Jay K.

PercAssist technology is designed for hemodynamic support and cardiac recovery – with simplicity, performance, and ease of use in mind for the patient and the clinician.   The PercAssist procedure is designed using a minimally invasive technique performed in the catheterization or hybrid lab. Proprietary ECG and implant technology applies ventricular compression synchronized with the patient’s natural heart rhythm. The implant does not reside in the bloodstream, reducing the possibility of anticoagulation therapy and the minimally invasive nature of the procedure is expected to shorten patient recovery time.   Initial use is anticipated in emergent conditions such as cardiogenic shock and severe acute decompensated heart failure. Future use is anticipated in longer-term support of advanced heart failure patients including bridge to transplant or destination therapy. Caution: The PercAssist technology is under development and is for investigational use only. Not approved by FDA and not available for commercial distribution in the United States or any other market.

TCA Venture Group Orange County (TCA OC) is part of TCA Venture Group (TCA VG), one of the largest angel investor groups in the U.S. TCA OC has been fueling the growth of innovative companies and entrepreneurs in Orange County and across the US and Canada since 1997. TCA OC identifies, mentors and funds early stage companies to help get their products to market. TCA OC members devote their time, expertise and capital to help companies grow and succeed. TCA Venture Group members number over 400 and consist of experienced CEOs, senior executives, current and former entrepreneurs, venture capitalists and other professionals. Members not only invest but frequently serve on boards and assist companies with relationships, strategy, supply chain, team building and additional fundraising. TCA VG has an outstanding deal flow of opportunities and a simplified yet organized process for screening and completing due diligence.

PercAssist technology is designed for hemodynamic support and cardiac recovery – with simplicity, performance, and ease of use in mind for the patient and the clinician.   The PercAssist procedure is designed using a minimally invasive technique performed in the catheterization or hybrid lab. Proprietary ECG and implant technology applies ventricular compression synchronized with the patient’s natural heart rhythm. The implant does not reside in the bloodstream, reducing the possibility of anticoagulation therapy and the minimally invasive nature of the procedure is expected to shorten patient recovery time.   Initial use is anticipated in emergent conditions such as cardiogenic shock and severe acute decompensated heart failure. Future use is anticipated in longer-term support of advanced heart failure patients including bridge to transplant or destination therapy. Caution: The PercAssist technology is under development and is for investigational use only. Not approved by FDA and not available for commercial distribution in the United States or any other market.

Founded in San Diego, CA, NuFund is one of the largest, most active and most successful early-stage investor groups over the past 20+ years. We represent diverse backgrounds and perspectives, and work together to foster a culture of excellence, respect, innovation, and fun.

Biosense Webster, Inc., part of Johnson and Johnson Medtech, is the global leader in the science, diagnosis and treatment of heart rhythm disorders. We partner with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. More information can be found at https://bit.ly/47DdIPR.